PRESSEPORTAL Presseportal Logo
All Stories
Follow
Subscribe to Stada Arzneimittel

09.12.2020 – 11:49

Stada Arzneimittel

STADA extends ViruProtect partnership with Enzymatica to cover Nordic region

One document

STADA extends ViruProtect partnership with Enzymatica to cover Nordic region

  • STADA has licensed from Enzymatica rights to market and sell ViruProtect® in Denmark, Finland, Iceland and Norway.
  • Having recently extended their partnership to cover Russia, Poland, Ukraine and 11 further countries in the CIS and Central Asia, STADA and Enzymatica now co-operate in more than 40 markets worldwide.
  • Steffen Wagner, Executive Vice-President, European Markets at STADA: "Having recently launched ViruProtect in several countries through our extensive European marketing and sales network, STADA is delighted to have extended our successful partnership with Enzymatica to cover Denmark, Finland, Iceland and Norway."

Bad Vilbel, Germany. 09 December 2020 - STADA Arzneimittel has extended its commercial partnership with Enzymatica AB (MSE:PHM) for ViruProtect Coldspray to cover four Nordic markets: Denmark, Finland, Iceland and Norway. Launches through STADA's local operations in these countries are scheduled during the course of 2021.

This latest extension to the ViruProtect partnership takes to more than 40 the number of countries in which STADA and Enzymatica now collaborate. Recently, STADA licensed from Enzymatica rights to ViruProtect, a class III medical device containing glycerol and the natural enzyme trypsin, in Russia, Poland, Ukraine and 11 further countries in the CIS and Central Asia.

Steffen Wagner, STADA's Executive Vice-President, European Markets, sees ViruProtect as a highly attractive addition to STADA's consumer healthcare portfolio in the Nordics region: "Having recently launched ViruProtect in several countries through our extensive European marketing and sales network, STADA is delighted to have extended our successful partnership with Enzymatica to cover Denmark, Finland, Iceland and Norway," he comments. "We look forward to using our strong relationships with pharmacies in these countries to bring an appealing product against common cold to patients and consumers, thereby delivering on our purpose of caring for people's health as a trusted partner."

"We are very satisfied for the continued trust by STADA. The interest by consumers for cold sprays is big and there is room for additional products alongside our own brand ColdZyme. The extended agreement shows also the strength of our barrier technology for the protection against common cold virus," says Claus Egstrand, Chief Operating Officer at Enzymatica.

Enzymatica - which estimates the combined value of the cough and cold market in Denmark, Norway, Finland and Iceland to be almost SEK 1.5 billion[1], or approximately EUR 150 million - has marketed and sold the cold spray under the ColdZyme brand name in the Danish and Norwegian markets since 2014, and in the Finnish market, through Tamro, since 2015. Enzymatica's subsidiary Zymetech has sold PreCold (ColdZyme) in Iceland since 2015.

Enzymatica will continue to sell its cold spray in Denmark, Norway and Iceland, and in parallel STADA will market ViruProtect in these markets. Both companies consider that there is room for several common cold sprays based on ColdZyme's successful barrier technology. In Finland, Tamro will continue to sell ColdZyme, while STADA will market the spray as ViruProtect.

In in vitro studies, the cold spray was effective against over 90% of main cold-causing viruses[2], and can shorten the duration of common cold in comparison to placebo.

About STADA Arzneimittel

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two-pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. STADA employs more than 12,400 people worldwide.

About Enzymatica AB

Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company's first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in 15 countries on 3 continents. The strategy is to continue to grow by developing more health care products and strengthening the company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases

Enzymatica's certified adviser is Erik Penser Bank. Phone: +46 (0)8 463 83 00. Email: certifiedadviser@penser.se

[1] Norsk Apotekerforening Total 2019, Dansk Aptekerforening Total 2019, Tamro MAT2019

[2] A medical device forms a protective barrier in the throat that deactivates five major common cold viruses. B. Stefansson, A. Gudmundsdottir, M. Clarsund, Swe ENT Congress 2018

Additional information for journalists :

STADA Arzneimittel AG / Media Relations
Stadastrasse 2-18 / 61118 Bad Vilbel / Germany 
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215
E-Mail: press@stada.de 

Or visit us on the Internet at www.stada.com/press

Additional information for capital market participants:

STADA Arzneimittel AG / Investor & Creditor Relations
Stadastrasse 2-18 / 61118 Bad Vilbel - Germany
Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215
 E-mail: ir@stada.de 

Or visit us on the Internet at www.stada.com/investor-relations